PT-141: Dosing Protocols

Dosing Information#

Dosing Overview#

PT-141 (bremelanotide/Vyleesi) has a well-established dosing regimen based on the Phase 3 RECONNECT clinical trials that led to FDA approval. Unlike most peptides covered on this site, which rely on preclinical data or anecdotal protocols, PT-141 has FDA-approved dosing with pharmacokinetic validation, dose-finding study justification, and safety monitoring data.

The approved dosing model is "as needed" (PRN), meaning the patient self-administers a single injection before anticipated sexual activity. This on-demand approach is one of PT-141's practical advantages compared to daily dosing regimens like flibanserin.

FDA-Approved Dosing#

Standard Dose#

Dose Selection Rationale#

The 1.75 mg dose was selected based on Phase 2 dose-finding studies that evaluated multiple dose levels. The dose-response analysis identified 1.75 mg as providing the optimal balance of efficacy and tolerability:

• Lower doses (0.75 mg, 1.25 mg) showed less consistent efficacy
• The 1.75 mg dose achieved statistically significant improvements in sexual desire and distress
• Higher doses did not provide additional efficacy but increased adverse events, particularly nausea
• The 1.75 mg dose was used in both Phase 3 RECONNECT trials

Pharmacokinetic Basis#

The dosing regimen is supported by the pharmacokinetic profile of PT-141:

The 45-minute pre-activity dosing allows time for PT-141 to reach peak concentrations and activate central MC4R pathways. The 2.7-hour half-life means that the drug's effects are present for a window of several hours, consistent with the on-demand use model.

Administration Instructions#

FDA-Approved Auto-Injector (Vyleesi)#

The approved commercial product is a single-dose prefilled auto-injector designed for patient self-administration:

1. Preparation: Remove the auto-injector from packaging. Allow to reach room temperature if refrigerated (not required for standard storage conditions)
2. Site selection: Choose an injection site on the abdomen or thigh
3. Skin preparation: Clean the injection site with an alcohol swab
4. Injection: Place the auto-injector against the skin, press the activation button, and hold in place for the recommended duration (typically 5-10 seconds after click)
5. Disposal: Dispose of the used auto-injector in a sharps container

Research-Grade Material Administration#

For research use with lyophilized PT-141:

1. Reconstitution: Dissolve lyophilized powder in bacteriostatic water at a known concentration
2. Draw dose: Using a 29-31 gauge insulin syringe, draw the calculated volume for 1.75 mg
3. Injection: Pinch skin at the abdomen or thigh, insert needle at 45-degree angle
4. Inject: Slowly inject over 5-10 seconds
5. Withdraw: Release skin, withdraw needle, apply gentle pressure

Concentration Calculations (Research Grade)#

Dosing Frequency Limitations#

Maximum 8 Doses Per Month#

The FDA label specifies a maximum of 8 doses per month. This limitation is based on:

• The clinical trial protocol, which allowed as-needed dosing up to daily
• Safety data showing that blood pressure effects are transient but occur with each dose
• The observation that focal hyperpigmentation may be dose-dependent and cumulative
• The desire to minimize chronic melanocortin receptor stimulation

24-Hour Minimum Interval#

The minimum 24-hour interval between doses ensures:

• Complete clearance of the previous dose (>8 half-lives)
• Return of blood pressure to baseline
• Prevention of drug accumulation
• Consistent with the as-needed therapeutic model

Male Sexual Dysfunction Dosing (Investigational)#

Phase 2 Study Protocols#

PT-141 has been studied in men with erectile dysfunction at the same 1.75 mg subcutaneous dose used in the female HSDD indication. The dosing parameters in male studies include:

• Dose: 1.75 mg subcutaneous
• Timing: Before anticipated sexual activity
• Frequency: As needed
• Combination: Co-administration with PDE5 inhibitors is under investigation

These male dosing protocols are investigational and not FDA-approved.

Special Populations#

Renal Impairment#

Approximately 65% of the PT-141 dose is excreted renally (primarily as metabolites). No formal dose adjustment has been established for patients with renal impairment. Patients with significant renal dysfunction may have altered exposure, and caution is advised.

Hepatic Impairment#

PT-141 is cleared primarily through peptide hydrolysis rather than hepatic metabolism. No dose adjustment has been established for hepatic impairment, but caution is recommended in the absence of formal study data.

Body Weight#

The 1.75 mg dose is not weight-adjusted. The Phase 3 trials enrolled women of varying body weights, and no significant effect of body weight on efficacy was reported. However, very low or very high body weight may affect pharmacokinetics.

Storage and Stability#

Vyleesi Commercial Product#

Research-Grade Lyophilized PT-141#

Stability Considerations#

PT-141's cyclic structure provides inherent stability advantages over linear peptides:

• The lactam bridge resists exopeptidase degradation
• The D-Phe residue resists endopeptidase degradation
• The norleucine substitution prevents methionine oxidation
• The primary degradation concern is tryptophan oxidation under UV light exposure

Comparison with Flibanserin Dosing#

Evidence Gaps#

• Dose optimization for male sexual dysfunction not established
• Whether dose titration (starting low) reduces nausea has not been systematically studied
• Optimal dosing in patients with renal or hepatic impairment undefined
• Whether chronic use beyond 12 months requires dose adjustment is unknown
• Combination dosing protocols with PDE5 inhibitors in development but not established
• Effect of food on PT-141 pharmacokinetics not formally studied (though SC administration bypasses GI tract)

Related Reading#

• PT-141 overview and research guide
• PT-141 side effects profile
• PT-141 research evidence